Molecular subgroups of medulloblastoma

The current consensus

Michael D. Taylor, Paul A. Northcott, Andrey Korshunov, Marc Remke, Yoon-Jae Cho, Steven C. Clifford, Charles G. Eberhart, D. Williams Parsons, Stefan Rutkowski, Amar Gajjar, David W. Ellison, Peter Lichter, Richard J. Gilbertson, Scott L. Pomeroy, Marcel Kool, Stefan M. Pfister

Research output: Contribution to journalArticle

793 Citations (Scopus)

Abstract

Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.

Original languageEnglish (US)
Pages (from-to)465-472
Number of pages8
JournalActa Neuropathologica
Volume123
Issue number4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Medulloblastoma
Demography
Age Factors
Transcriptome
Terminology
Cerebellum
Histology
Cohort Studies
Pediatrics
Neoplasm Metastasis
Morbidity
Mortality
Research
Neoplasms

Keywords

  • Consensus
  • Group 3
  • Group 4
  • Medulloblastoma
  • SHH
  • Subgroups
  • WNT

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y-J., Clifford, S. C., ... Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathologica, 123(4), 465-472. https://doi.org/10.1007/s00401-011-0922-z

Molecular subgroups of medulloblastoma : The current consensus. / Taylor, Michael D.; Northcott, Paul A.; Korshunov, Andrey; Remke, Marc; Cho, Yoon-Jae; Clifford, Steven C.; Eberhart, Charles G.; Parsons, D. Williams; Rutkowski, Stefan; Gajjar, Amar; Ellison, David W.; Lichter, Peter; Gilbertson, Richard J.; Pomeroy, Scott L.; Kool, Marcel; Pfister, Stefan M.

In: Acta Neuropathologica, Vol. 123, No. 4, 01.04.2012, p. 465-472.

Research output: Contribution to journalArticle

Taylor, MD, Northcott, PA, Korshunov, A, Remke, M, Cho, Y-J, Clifford, SC, Eberhart, CG, Parsons, DW, Rutkowski, S, Gajjar, A, Ellison, DW, Lichter, P, Gilbertson, RJ, Pomeroy, SL, Kool, M & Pfister, SM 2012, 'Molecular subgroups of medulloblastoma: The current consensus', Acta Neuropathologica, vol. 123, no. 4, pp. 465-472. https://doi.org/10.1007/s00401-011-0922-z
Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, Clifford SC et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathologica. 2012 Apr 1;123(4):465-472. https://doi.org/10.1007/s00401-011-0922-z
Taylor, Michael D. ; Northcott, Paul A. ; Korshunov, Andrey ; Remke, Marc ; Cho, Yoon-Jae ; Clifford, Steven C. ; Eberhart, Charles G. ; Parsons, D. Williams ; Rutkowski, Stefan ; Gajjar, Amar ; Ellison, David W. ; Lichter, Peter ; Gilbertson, Richard J. ; Pomeroy, Scott L. ; Kool, Marcel ; Pfister, Stefan M. / Molecular subgroups of medulloblastoma : The current consensus. In: Acta Neuropathologica. 2012 ; Vol. 123, No. 4. pp. 465-472.
@article{9e9bfd7244da47b7867bc4536ecc2297,
title = "Molecular subgroups of medulloblastoma: The current consensus",
abstract = "Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.",
keywords = "Consensus, Group 3, Group 4, Medulloblastoma, SHH, Subgroups, WNT",
author = "Taylor, {Michael D.} and Northcott, {Paul A.} and Andrey Korshunov and Marc Remke and Yoon-Jae Cho and Clifford, {Steven C.} and Eberhart, {Charles G.} and Parsons, {D. Williams} and Stefan Rutkowski and Amar Gajjar and Ellison, {David W.} and Peter Lichter and Gilbertson, {Richard J.} and Pomeroy, {Scott L.} and Marcel Kool and Pfister, {Stefan M.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1007/s00401-011-0922-z",
language = "English (US)",
volume = "123",
pages = "465--472",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Molecular subgroups of medulloblastoma

T2 - The current consensus

AU - Taylor, Michael D.

AU - Northcott, Paul A.

AU - Korshunov, Andrey

AU - Remke, Marc

AU - Cho, Yoon-Jae

AU - Clifford, Steven C.

AU - Eberhart, Charles G.

AU - Parsons, D. Williams

AU - Rutkowski, Stefan

AU - Gajjar, Amar

AU - Ellison, David W.

AU - Lichter, Peter

AU - Gilbertson, Richard J.

AU - Pomeroy, Scott L.

AU - Kool, Marcel

AU - Pfister, Stefan M.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.

AB - Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.

KW - Consensus

KW - Group 3

KW - Group 4

KW - Medulloblastoma

KW - SHH

KW - Subgroups

KW - WNT

UR - http://www.scopus.com/inward/record.url?scp=84860821444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860821444&partnerID=8YFLogxK

U2 - 10.1007/s00401-011-0922-z

DO - 10.1007/s00401-011-0922-z

M3 - Article

VL - 123

SP - 465

EP - 472

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 4

ER -